1. Combination therapy in neuroblastoma: It`s all about the mix

    The combination of two cell division inhibitors causes malignant nervous system tumors to die off, as scientists from the “Hopp Children’s Cancer Center at the NCT Heidelberg” (KiTZ) have shown in experimental studies.The combination strategy could be the key to new targeted therapies against this aggressive type of tumor. The Hopp Children’s Cancer Center at […]

    The post Combination therapy in neuroblastoma: It`s all about the mix appeared first on Healthcanal.com.

    Read Full Article
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video

    1. We have found that the effects of the HDAC8 inhibitor and the ALK inhibitor crizotinib add up, and that the two compounds together are significantly more effective than the two inhibitors alone.
    2. In tissue cultures, this combination strategy not only stopped growth, but even induced programmed cell death in neuroblastoma cells.
    3. We hope that we will soon be able to transfer our experimental analyses to clinical trials.
  3. Topics Mentioned

  4. Authors